News Center

Home page

Peak Report

News reports

Announcement on Receiving Performance Compensation for Foreign Investment of Subsidiators

Release time:

2020-08-05

Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2018-034

Bond Abbreviation: 13 Peak 02 Bond Code: 122344

Announcement of Zhejiang Jianfeng Group Co., Ltd.

on Performance Compensation Received by Subsidiaries for Foreign Investment

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

Basic Information on 1. Performance Commitment

On February 28, 2017, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a subsidiary of the Company, and Guilin Shangyuan Plant Products Co., Ltd. (hereinafter referred to as "Guilin Shangyuan") and Beijing Huibaoyuan Enterprise Management Co., Ltd. (hereinafter referred to: beihui Management) and Beijing Huibaoyuan Biotechnology Co., Ltd. (hereinafter referred to as: Beihui Biotechnology) signed the "Agreement on Capital Increase and Equity Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." (hereinafter referred to as: "Master Agreement"), "Performance Commitment Compensation Agreement", agreed that under the premise of meeting the investment conditions of each period, Jianfeng Pharmaceutical intends to increase capital and transfer equity, investment in Beihui Biology in stages.

According to the Performance Commitment Compensation Agreement, Beihui Management and Guilin Shangyuan have made commitments to the target net profit of Beihui Biology in each year of the compensation period. If the actual net profit of Beihui Biology in a certain year is lower than the target net profit promised in the current period, Beihui Management and Guilin Shangyuan will compensate Jianfeng Pharmaceutical in the form of cash or shares. For details, please refer to the announcement

-Pro 2017-003

"Announcement on Foreign Investment of Subsidiators" published by the company in the designated information disclosure media "shanghai securities news", "china securities journal" and the website of Shanghai Stock Exchange (www.sse.com.cn ) on March 1, 2017.

2. Performance Commitment Compensation

(I) Jianfeng Pharmaceutical has completed the first phase of investment in 80 million yuan. Beihui Biology's registered capital has increased from 80 million yuan to 100 million yuan, of which Jianfeng Pharmaceutical holds 20 million shares, with a shareholding ratio of 20%.

(II) Beihui Biology's holding subsidiary Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd.'s newly-built production base located in the "China-Malaysia Qinzhou Industrial Park" is in the GMP certification stage and has not yet been fully put into production. Due to large investment and other reasons, Beihui Biology suffered a net profit loss attributable to the owner of the parent company in 2017. According to CAC Special Zi [2018] No. 0955 "Verification Report on Performance Commitments of Beijing Huibaoyuan Biotechnology Co., Ltd." issued by China Certified Public Accountants (Special General Partnership), Beihui Biotechnology's net profit attributable to the owner of the parent company in 2017 was -37.3434 million yuan, and failed to fulfill its performance promise of "achieving break-even in 2017. Beihui Management and Guilin Shangyuan shall pay 7.4687 million yuan as compensation for 2017 annual performance to Jianfeng Pharmaceutical.

The (III) Commitment Party decided that Beihui Management would choose shares to compensate Jianfeng Pharmaceutical. According to the agreement of the Performance Commitment Compensation Agreement, Beihui Management would transfer its 1,867,169 shares of Beihui Biology to Jianfeng Pharmaceutical at the price (4 yuan/share) of the latest capital increase from Jianfeng Pharmaceutical to Beihui Biology, and compensate Jianfeng Pharmaceutical with the obtained 7.4687 million yuan equity transfer.

On December 25, 2018, Beihui Bio received the "Filing Notice" from the registration agency, and has completed the registration procedures for the change of the above-mentioned shares. Peak Pharmaceutical has also received the compensation of 7.4687 million yuan paid by Beihui Management. So far, Beihui Management has fulfilled the agreement of the Performance Commitment Compensation Agreement and completed the performance compensation for 2017.

As of the announcement date, Peak Pharmaceuticals holds a total of 21,867,169 shares of Beihui Bio, with a shareholding ratio of 21.87.

is hereby announced

Zhejiang Jianfeng Group Co., Ltd. Board of Directors

December 27, 2018

More information

The company organized "charity one day donation"

On the morning of October 22, in the lobby on the first floor of Jianfeng Building, all cadres and employees of the group headquarters and subordinate enterprises working in Jianfeng Building participated in the 2021 "Charity Day Donation" activity to offer their love to Jinhua charity. In the next few days, the company's subordinate enterprises also organized "charity one-day donation" activities one after another.

2021

11-01

The company organizes new employee induction training

"Growth is more important than success. I hope everyone can become the backbone and pillars of the peak as soon as possible." On September 2, Yu Jianhong, general manager of the group company, put forward ardent hopes in the face of new employees. On the 2nd and 3rd, the group company organized induction training for new employees recruited in the past year. The group company chairman Jiang Xiaomeng, general manager Yu Jianhong and other leaders and relevant department heads gave lectures to them.

2021

09-13

Daye Peak: Typical Regional Industrial Green Development

On August 23, Huangshi Radio and Television Station broadcast the special program of "Strengthening Overall Planning and Promoting Energy Saving and Emission Reduction in Industrial Field". Daye Jianfeng Cement Company, as a typical enterprise with outstanding achievements in establishing green factories and energy saving and emission reduction in Huangshi area, appeared in the program.

2021

09-01

Yunnan Peak Helps Border Epidemic Prevention and Control

On August 22, Yunnan Peak Cement Company, through the Red Cross Society of Pu'er City and the Epidemic Prevention Headquarters of Pu'er City, donated vacuum insulation pots with a total value of 800000 yuan to the four border counties for the prevention and control of the new coronary pneumonia epidemic in the border area, and supported the prevention and control of the epidemic at the border with practical actions.

2021

09-01

Group Party Committee to Learn "July 1" Important Speech

On August 13, the party committee of the group company held a special meeting to collectively study General Secretary Xi Jinping's important speech at the celebration meeting of the 100 anniversary of the founding of the Communist Party of China, convey the requirements of the party committee at a higher level, and make arrangements for organizing party members of the company to study the "July 1" speech.

2021

08-23

Spike Ranked 2020 China's Top 100 Cement Clinker Production Capacity

Recently, the company received the "2020 China Cement Clinker Production Capacity Top 100" plaque issued by China Cement Network. The ranking of China's top 100 cement clinker production capacity is organized and evaluated by China Cement Network, an authoritative information platform for the domestic cement industry. It is released according to the actual clinker production capacity of each cement enterprise at the end of last year. The company has been ranked in the top 100 list for many consecutive years.

2021

08-23

< 1...8 9 10...61 > 跳转到页